0001654954-18-009423.txt : 20180820 0001654954-18-009423.hdr.sgml : 20180820 20180820170341 ACCESSION NUMBER: 0001654954-18-009423 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180820 DATE AS OF CHANGE: 20180820 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PREMIER BIOMEDICAL INC CENTRAL INDEX KEY: 0001515740 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 272635666 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54563 FILM NUMBER: 181028795 BUSINESS ADDRESS: STREET 1: P.O. BOX 25 CITY: JACKSON CENTER STATE: PA ZIP: 16133 BUSINESS PHONE: 724-633-7033 MAIL ADDRESS: STREET 1: P.O. BOX 25 CITY: JACKSON CENTER STATE: PA ZIP: 16133 10-Q 1 biei_10q.htm QUARTERLY REPORT Blueprint
 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 10-Q
 
(Mark One)
 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended June 30, 2018
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from _______________ to _______________.
 
Commission File Number: 000-54563
 
PREMIER BIOMEDICAL, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
 
27-2635666
 (State or other jurisdiction of incorporation or organization)
 
 (I.R.S. Employer Identification No.)
 
P.O. Box 25
Jackson Center, PA
 
16133
 (Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code (814) 786-8849
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☑ No ☐
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
(Do not check if a smaller reporting company)
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑ 
 
As of August 16, 2018, there were 3,255,973 shares of common stock, $0.00001 par value, issued and outstanding.
 

 
 
 
PREMIER BIOMEDICAL, INC.
 
TABLE OF CONTENTS
 
PART I – FINANCIAL INFORMATION
1
       
 
ITEM 1    Financial Statements
1
       
 
ITEM 2    Management’s Discussion and Analysis of Financial Condition and Results of Operations
17
       
 
ITEM 3    Quantitative and Qualitative Disclosures About Market Risk
23
       
 
ITEM 4    Controls and Procedures
23
 
 
PART II – OTHER INFORMATION
24
 
 
ITEM 1    Legal Proceedings
24
       
 
ITEM 1A    Risk Factors
24
       
 
ITEM 2    Unregistered Sales of Equity Securities and Use of Proceeds
24
       
 
ITEM 3    Defaults Upon Senior Securities
24
       
 
ITEM 4    Mine Safety Disclosures
24
       
 
ITEM 5    Other Information
24
       
 
ITEM 6    Exhibits
24
 
 
 

2
 
 
PREMIER BIOMEDICAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
 
 
 
June 30,
 
 
December 31,
 
 
 
2018
 
 
2017
 
ASSETS
 
 (Unaudited)
 
 
 
 
 
 
 
 
 
 
 
Current assets:
 
 
 
 
 
 
Cash
 $10,319 
 $83,704 
Accounts receivable
  - 
  312 
Inventory
  123,416 
  84,763 
Other current assets
  35,774 
  34,824 
Total current assets
  169,509 
  203,603 
 
    
    
Property and equipment, net
  6,313 
  5,478 
 
    
    
Total assets
 $175,822 
 $209,081 
 
    
    
 
    
    
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
    
    
 
    
    
Current liabilities:
    
    
Accounts payable
 $347,560 
 $346,814 
Accounts payable, related parties
  36,746 
  41,382 
Accrued interest
  13,895 
  5,840 
Convertible notes payable, net of discounts of $36,640 and $30,010
    
    
at June 30, 2018 and December 31, 2017, respectively, currently in default
  218,360 
  169,990 
Derivative liabilities
  1,586,399 
  2,255,781 
Total current liabilities
  2,202,960 
  2,819,807 
 
    
    
Total liabilities
  2,202,960 
  2,819,807 
 
    
    
Commitments and contingencies
  - 
  - 
 
    
    
Stockholders' equity (deficit):
    
    
Preferred stock, $0.001 par value, 10,000,000 shares
    
    
authorized, 2,000,000 shares issued and outstanding
    
    
at June 30, 2018 and December 31, 2017
  2,000 
  2,000 
Common stock, $0.00001 par value, 1,000,000,000 shares
    
    
authorized, 2,989,307 and 2,551,363 shares issued and
    
    
outstanding at June 30, 2018 and December 31, 2017, respectively
  30 
  26 
Additional paid in capital
  13,833,326 
  13,442,255 
Subscriptions payable, consisting of -0- and 254,703 shares
    
    
at June 30, 2018 and December 31, 2017, respectively
  - 
  273,805 
Accumulated deficit
  (15,862,494)
  (16,328,812)
Total stockholders' equity (deficit)
  (2,027,138)
  (2,610,726)
 
    
    
Total liabilities and stockholders' equity (deficit)
 $175,822 
 $209,081 
 
See accompanying notes to financial statements.
 
 
3
 
 
PREMIER BIOMEDICAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
 
 
 
For the Three Months
 
 
For the Six Months
 
 
 
Ended June 30,
 
 
Ended June 30,
 
 
 
2018
 
 
2017
 
 
2018
 
 
2017
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue
 $12,089 
 $- 
 $22,484 
 $- 
Cost of goods sold
  10,146 
  - 
  16,204 
  - 
Gross profit
  1,943 
  - 
  6,280 
  - 
 
    
    
    
    
Operating expenses:
    
    
    
    
General and administrative
  42,817 
  40,246 
  77,309 
  73,305 
Professional fees
  38,724 
  45,609 
  78,340 
  86,756 
Total operating expenses
  81,541 
  85,855 
  155,649 
  160,061 
 
    
    
    
    
Net operating loss
  (79,598)
  (85,855)
  (149,369)
  (160,061)
 
    
    
    
    
Other income (expense):
    
    
    
    
Interest expense
  (73,554)
  (600)
  (137,699)
  (153,347)
Change in derivative liabilities
  53,146 
  (1,161,010)
  753,386 
  (6,261,101)
Equity in losses of investment in joint venture
  - 
  - 
  - 
  (2,058)
Total other income (expense)
  (20,408)
  (1,161,610)
  615,687 
  (6,416,506)
 
    
    
    
    
Net income (loss)
 $(100,006)
 $(1,247,465)
 $466,318 
 $(6,576,567)
 
    
    
    
    
 
    
    
    
    
Weighted average number of common shares outstanding - basic
  2,989,307 
  2,008,700 
  2,932,577 
  1,808,032 
Weighted average number of common shares outstanding - fully diluted
  2,989,307 
  2,008,700 
  2,944,497 
  1,808,032 
 
    
    
    
    
Net income (loss) per share - basic
 $(0.03)
 $(0.62)
 $0.16 
 $(3.64)
Net income (loss) per share - fully diluted
 $(0.03)
 $(0.62)
 $0.16 
 $(3.64)
 
See accompanying notes to financial statements.
 
 
4
 
 
PREMIER BIOMEDICAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
 
 
 
For the Six Months
 
 
 
Ended June 30,
 
 
 
2018
 
 
2017
 
CASH FLOWS FROM OPERATING ACTIVITIES
 
 
 
 
 
 
Net income (loss)
 $466,318 
 $(6,576,567)
Adjustments to reconcile net income (loss)
    
    
to net cash used in operating activities:
    
    
Depreciation
  1,194 
  1,191 
Equity in losses of joint venture investment
  - 
  2,058 
Change in fair market value of derivative liabilities
  (753,386)
  6,261,101 
Amortization of debt discounts
  129,644 
  149,456 
Decrease (increase) in assets:
    
    
Accounts receivable
  312 
  - 
Inventory
  (38,653)
  - 
Other current assets
  (950)
  (130,091)
Increase (decrease) in liabilities:
    
    
Accounts payable
  746 
  (57,653)
Accounts payable, related parties
  (4,636)
  947 
Accrued interest
  8,055 
  2,691 
Accrued interest, related parties
  - 
  1,200 
Net cash used in operating activities
  (191,356)
  (345,667)
 
    
    
CASH FLOWS FROM INVESTING ACTIVITIES
    
    
Purchases of property and equipment
  (2,029)
  (2,694)
Investment in joint venture
  - 
  (2,058)
Net cash used in investing activities
  (2,029)
  (4,752)
 
    
    
CASH FLOWS FROM FINANCING ACTIVITIES
    
    
Proceeds from sale of stock, net of offering costs
  - 
  435,000 
Proceeds from sale of stock on equity line of credit
  - 
  18,323 
Proceeds from convertible notes payable
  120,000 
  - 
Net cash provided by financing activities
  120,000 
  453,323 
 
    
    
NET CHANGE IN CASH
  (73,385)
  102,904 
CASH AT BEGINNING OF PERIOD
  83,704 
  22,437 
 
    
    
CASH AT END OF PERIOD
 $10,319 
 $125,341 
 
    
    
SUPPLEMENTAL INFORMATION:
    
    
Interest paid
 $- 
 $- 
Income taxes paid
 $- 
 $- 
 
    
    
NON-CASH INVESTING AND FINANCING ACTIVITIES:
    
    
Value of debt discounts
 $120,000 
 $- 
Value of derivative adjustment due to debt conversions
 $52,270 
 $229,043 
Value of shares issued for conversion of debt
 $65,000 
 $323,197 
 
See accompanying notes to financial statements.
 
 
5
Premier Biomedical, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
 
Note 1 – Basis of Presentation and Significant Accounting Policies
 
Basis of Presentation
The accompanying unaudited, condensed financial statements of Premier Biomedical, Inc. (“the Company”) have been prepared pursuant to rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, these statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. It is suggested that these statements be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.
 
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
 
Cash and Cash Equivalents
We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents.
 
Patent Rights and Applications
Patent rights and applications costs include the acquisition costs and costs incurred for the filing of patents. Patent rights and applications are amortized on a straight-line basis over the legal life of the patent rights beginning at the time the patents are approved. Patent costs for unsuccessful patent applications are expensed when the application is terminated.
 
Fair Value of Financial Instruments
Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments.
 
Basic and Diluted Loss Per Share
Basic earnings per share (“EPS”) are computed by dividing net income (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Diluted EPS is computed by dividing net income by the weighted average number of common shares and potential common shares outstanding (if dilutive) during each period. Potential common shares include stock options, warrants and restricted stock. The number of potential common shares outstanding relating to stock options, warrants and restricted stock is computed using the treasury stock method.
 
 
6
Premier Biomedical, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
 
The reconciliation of the denominators used to calculate basic EPS and diluted EPS for the six months ended June 30, 2018 and 2017 are as follows:
 
 
 
For the Six Months Ended
 
 
 
June 30,
 
 
 
2018
 
 
2017
 
Weighted average common shares outstanding – basic
  2,932,577 
  1,808,032 
Plus: Potentially dilutive common shares:
    
    
Warrants
  11,920 
  - 
Weighted average common shares outstanding – diluted
  2,944,497 
  1,808,032 
 
For the six months ended June 30, 2017, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share. Warrants excluded from the calculation of diluted EPS because their effect was anti-dilutive were 245,760 and 685,184 as of June 30, 2018 and 2017, respectively.
 
Stock-Based Compensation
Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company had no stock based compensation issuances during the six months ended June 30, 2018 and 2017.
 
Revenue Recognition
Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales commenced on July 5, 2017 with the termination of our joint venture and are recognized upon shipment of goods, which are typically paid for at the time of order.
 
Advertising and Promotion
All costs associated with advertising and promoting products are expensed as incurred. These expenses were $20,742 and $25,413 for the six months ended June 30, 2018 and 2017, respectively.
 
Income Taxes
Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.
 
Uncertain Tax Positions
In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.
 
Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities.
 
The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.
 
 
7
Premier Biomedical, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
 
Recent Accounting Pronouncements
In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The new guidance is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, with early adoption permitted. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.
 
In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118. The amendment provides guidance on accounting for the impact of the Tax Cuts and Jobs Act (the “Tax Act”) and allows entities to complete the accounting under ASC 740 within a one-year measurement period from the Tax Act enactment date. This standard is effective upon issuance. The Tax Act has several significant changes that impact all taxpayers, including a transition tax, which is a one-time tax charge on accumulated, undistributed foreign earnings. The calculation of accumulated foreign earnings requires an analysis of each foreign entity’s financial results going back to 1986. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.
 
In February 2018, the FASB issued ASU No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The guidance permits entities to reclassify tax effects stranded in Accumulated Other Comprehensive Income as a result of tax reform to retained earnings. This new guidance is effective for annual and interim periods in fiscal years beginning after December 15, 2018. Early adoption is permitted in annual and interim periods and can be applied retrospectively or in the period of adoption. The Company is currently in the process of evaluating the impact of adoption on its consolidated financial statements.
 
Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. There was no impact on the Company’s financial statements as a result of adopting Topic 606 for the six months ended June 30, 2018 and 2017, or the twelve months ended December 31, 2017.
 
In May 2017, the FASB issued ASU 2017-09, Compensation — Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. Per ASU 2017-9, an entity should account for the effects of a modification unless all the following are met: (1) the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification, (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and (3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The current disclosure requirements in Topic 718 apply regardless of whether an entity is required to apply modification accounting under the amendments in ASU 2017-9. ASU 2017-9 is effective for public business entities for annual and interim periods in fiscal years beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this ASU should be applied prospectively to an award modified on or after the adoption date. The adoption of ASU 2017-9 is not expected to have a material impact on the Company’s financial statements or related disclosures.
 
No other new accounting pronouncements, issued or effective during the six months ended June 30, 2018, have had or are expected to have a significant impact on the Company’s financial statements.
 
 
8
Premier Biomedical, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
 
Note 2 – Going Concern
 
As shown in the accompanying financial statements, the Company has no revenues, incurred net losses from operations resulting in an accumulated deficit of $15,862,494, and had negative working capital of ($2,033,451) at June 30, 2018. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company is currently seeking additional sources of capital to fund short term operations. The Company, however, is dependent upon its ability to secure equity and/or debt financing and there are no assurances that the Company will be successful; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern.
 
The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. The financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.
 
Note 3 – Related Parties
 
Accounts Payable
The Company owed $34,116 and $40,195 as of June 30, 2018 and December 31, 2017, respectively, to entities owned by the Chairman of the Board of Directors. The amounts are related to patent costs and reimbursable expenses paid by the Chairman on behalf of the Company.
 
The Company owed $1,555 as of June 30, 2018 and December 31, 2017, to the Company’s CEO for reimbursable expenses.
 
The Company owed $1,075 and $478 as of June 30, 2018 and December 31, 2017, respectively, amongst members of the Company’s Board of Directors for reimbursable expenses.
 
Note 4 – Subsidiary Formation
 
On September 14, 2017, we formed Premier Biomedical Pain Relief Meds, LLC as a wholly-owned Nevada limited liability company. On January 1, 2018, we contributed our pain management assets to this entity and continued our pain management operations within this new subsidiary.
 
Note 5 – Patent Rights and Applications
 
The Company amortizes its patent rights and applications on a straight line basis over the expected useful technological or economic life of the patents, which is typically 17 years from the legal approval of the patent applications when there is probable future economic benefits associated with the patent. The Company has elected to expense all of their patent rights and application costs due to difficulties associated with having to prove the value of their future economic benefits. All patent applications are currently pending and the Company has no patents that have yet been approved. It is the Company’s policy that it performs reviews of the carrying value of its patent rights and applications on an annual basis.
 
On March 4, 2015, we entered into a Patent License Agreement (“PLA”) with the University of Texas at El Paso (“UTEP”) regarding our joint research and development of CTLA-4 Blockade with Metronomic Chemotherapy for the Treatment of Breast Cancer. This is the first PLA with UTEP following our Collaborative Agreement with them dated May 9, 2012, and memorializes the joint ownership of the applicable patent and the financial and other terms related thereto.
 
On June 19, 2015, we entered into Amendment No. 1 to this Agreement, pursuant to which we explicitly included Provisional Patent Application No. 62/161,116 entitled, “Anti-CTLA-4 Blockade” (the “Application”) under the definition of “Patent Rights” as set forth in the PLA. The Application was filed with the United States Patent and Trademarks Office on May 13, 2015; the underlying technology was invented by Robert Kirken and Georgialina Rodriguez, and is solely-owned by The Board of Regents of The University of Texas System.
 
 
9
Premier Biomedical, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
 
Note 6 – Fair Value of Financial Instruments
 
Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value.
 
The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows:
 
Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
 
Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
 
Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability.
 
The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2018 and December 31, 2017, respectively:
 
 
 
Fair Value Measurements at June 30, 2018
 
 
 
Level 1
 
 
Level 2
 
 
Level 3
 
Assets
 
 
 
 
 
 
 
 
 
Cash
 $10,319 
 $- 
 $- 
Total assets
  10,319 
  - 
  - 
Liabilities
    
    
    
Convertible notes payable, net of discounts
    
  218,360 
    
Derivative liabilities
  - 
  - 
  1,586,399 
Total liabilities
  - 
  218,360 
  1,586,399 
 
 $10,319 
 $(218,360)
 $(1,586,399)
 
 
 
Fair Value Measurements at December 31, 2017
 
 
 
Level 1
 
 
Level 2
 
 
Level 3
 
Assets
 
 
 
 
 
 
 
 
 
Cash
 $83,704 
 $- 
 $- 
Total assets
  83,704 
  - 
  - 
Liabilities
    
    
    
Convertible note payable, net of discounts
  - 
  169,990 
  - 
Derivative liabilities
  - 
  - 
  2,255,781 
Total liabilities
  - 
  169,990 
  2,255,781 
 
 $83,704 
 $(169,990)
 $(2,255,781)
 
The fair values of our related party debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35.
 
There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the six months ended June 30, 2018 or the year ended December 31, 2017.
 
 
10
Premier Biomedical, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
  
Note 7 – Convertible Notes Payable, Currently in Default
 
Convertible notes payable consist of the following at June 30, 2018 and December 31, 2017, respectively:
 
 
 
June 30,
 
 
December 31,
 
 
 
2018
 
 
2017
 
 
 
 
 
 
 
 
On April 24, 2018, the Company received proceeds of $30,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on July31, 2018 (“Second Red Diamond Note”). The note is convertible at 60% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.$
  30,000 
 $- 
 
    
    
On April 24, 2018, the Company received proceeds of $30,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on July 31, 2018 (“Second SEG-RedaShex Note”). The note is convertible at 60% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
  30,000 
  - 
 
    
    
On March 1, 2018, the Company received proceeds of $30,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on May 31, 2018 (“First Red Diamond Note”). The note is convertible at 60% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
  30,000 
  - 
 
    
    
On March 1, 2018, the Company received proceeds of $30,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on May 31, 2018 (“First SEG-RedaShex Note”). The note is convertible at 60% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
  30,000 
  - 
 
    
    
On October 30, 2017, the Company received proceeds of $50,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on January 31, 2018 (“Second Diamond Rock Note”). The note is convertible at 60% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Currently in default.
  50,000 
  50,000 
 
    
    
On October 30, 2017, the Company received proceeds of $50,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on January 31, 2018 (“Second SEG Note”). The note is convertible at 60% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $10,000 of principal was converted into 5,208,333 shares of common stock on October 31, 2017, and the remaining $40,000 of principal was converted into 26,559,426 shares of common stock on January 29, 2018.
  - 
  40,000 
 
    
    
 
 
11
Premier Biomedical, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
 
On August 8, 2017, the Company entered into an exchange agreement with Diamond Rock, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First Diamond Rock Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $15,000 of principal was converted into an aggregate of 7,812,500 shares of common stock at various dates between November 6, 2017 and November 13, 2017. Currently in default.
  35,000 
  35,000 
 
 
 
    
    
On August 8, 2017, the Company entered into an exchange agreement with The Special Equities Group, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First SEG Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Currently in default.
  50,000 
  50,000 
 
 
 
    
    
On August 8, 2017, the Company entered into an exchange agreement with RDW Capital, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First RDW Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $25,000 of principal was converted into 13,157,895 shares of common stock on October 31, 2017, and the remaining $25,000 of principal was converted into 19,230,769 shares of common stock on January 3, 2018.
  - 
  25,000 
 
    
    
Total convertible notes payable, currently in default
  255,000 
  200,000 
Less unamortized derivative discounts:
  36,640 
  30,010 
Convertible notes payable
  218,360 
  169,990 
Less: current portion
  218,360 
  169,990 
Convertible notes payable, less current portion$
  - 
 $- 
 
The Company recognized interest expense for the six months ended June 30, 2018 and 2017, respectively, as follows:
 
 
 
June 30,
 
 
June 30,
 
 
 
2018
 
 
2017
 
 
 
 
 
 
 
 
Interest on convertible notes
 $8,055 
 $2,691 
Interest on related party loans
  - 
  1,200 
Derivative discounts
  129,644 
  149,456 
Total interest expense
 $137,699 
 $153,347 
 
 
12
Premier Biomedical, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
 
 
Note 8 – Derivative Liabilities
 
As discussed in Note 7 under Convertible Notes Payable, the Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted and all additional convertible debentures and warrants are included in the value of the derivative. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion option and warrants and shares to be issued were recorded as derivative liabilities on the issuance date.
 
The fair values of the Company’s derivative liabilities were estimated at the issuance date and are revalued at each subsequent reporting date, using a lattice model. The Company recognized current derivative liabilities of $1,586,399 and $2,255,781 at June 30, 2018 and December 31, 2017, respectively. The change in fair value of the derivative liabilities resulted in a gain of $753,386 and a loss of $6,261,101 for the six months ended June 30, 2018 and 2017, respectively, which has been reported within other expense in the statements of operations. The gain of $753,386 for the six months ended June 30, 2018 consisted of a gain of $766,489 due to the value attributable to the warrants and a net loss in market value of $13,103 on the convertible notes. The loss of $6,261,101 for the six months ended June 30, 2017 consisted of a loss of $7,103,444 due to the value attributable to the warrants, a gain of $849,564 in market value of the warrants and a net loss in market value of $7,221 on the convertible notes.
 
The following is a summary of changes in the fair market value of the derivative liability during the six months ended June 30, 2018 and the year ended December 31, 2017, respectively:
 
 
 
Derivative
 
 
 
Liability
 
 
 
Total
 
Balance, December 31, 2016
 $221,822 
Increase in derivative value due to issuances of convertible promissory notes
  221,515 
Increase in derivative value attributable to tainted warrants
  7,103,444 
Decrease in derivative value attributable to exchange of warrants
  (3,766,437)
Change in fair market value of derivative liabilities due to the mark to market adjustment
  (1,221,021)
Debt conversions
  (303,542)
Balance, December 31, 2017
 $2,255,781 
Increase in derivative value due to issuances of convertible promissory notes
  136,274 
Change in fair market value of derivative liabilities due to the mark to market adjustment
  (753,386)
Debt conversions
  (52,270)
Balance, June 30, 2018
 $1,586,399 
 
Key inputs and assumptions used to value the convertible debentures and warrants issued during the six months ended June 30, 2018:
Stock price ranging from $0.825 to $0.3799 during these periods would fluctuate with projected volatility.
The notes convert with variable conversion prices and fixed conversion prices (tainted notes).
An event of default would occur -0-% of the time, increasing 2% per month to a maximum of 10%.
The projected annual volatility curve for each valuation period was based on the historical annual volatility of the company in the range of 163.5% - 155.1%.
The Company would redeem the notes -0-% of the time, increasing 1% per month to a maximum of 5%.
All notes are assumed to be extended at maturity by 2 years – the time required to convert out this volume of stock.
The holders of the securities would automatically convert midway through to maturity on a monthly basis based on ownership and trading volume limitations.
A change of control and fundamental transaction would occur initially -0-% of the time and increase monthly by -0-% to a maximum of -0-%.
 
 
13
Premier Biomedical, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
 
The monthly trading volume would average $977,628 to $1,011,971 and would increase at 1% per month.
The stock price would fluctuate with the Company projected volatility using a random sampling (500,000 iterations for each valuation) from a normal distribution. The stock price of the underlying instrument is modelled such that it follows a geometric Brownian motion with constant drift and volatility.
The Holder would exercise the warrants after one trading day as they become exercisable (at issuance) at target prices of 3 to 5 times the projected reset price or higher.
Reset events were projected to occur by 12/31/18 – the reset provision ends 3/30/19 and the option expires 3/30/20.
The stock price would fluctuate with an annual volatility. The projected annual volatility curve for each valuation period was based on the historical annual volatility of the company and the term remaining in the range 176.6% - 181%.
The Holder would exercise the warrant at maturity in 2020 if the stock price was above the reset exercise price.
 
Note 9 – Commitments and Contingencies
 
Collaborative Patent License Agreements
On May 9, 2012, the Company entered into a Collaborative Agreement with the University of Texas at El Paso. Pursuant to the terms of the Agreement, the Company will work jointly with the University to develop a series of research and development programs around its sequential-dialysis technology in the areas of Alzheimer's Disease, Traumatic Brain Injury (TBI), Chronic Pain Syndrome, Fibromyalgia, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease), Blood Sepsis, Cancer, Heart Attacks and Strokes. The programs will utilize the facilities at one or more of the University of Texas’ campuses. The Company will pay the University’s actual overhead for the projects, plus a negotiated facility and administration overhead expense, and 10% of all gross revenues associated with the sale, license and/or royalties of all products and treatment procedures directly affiliated with programs. Intellectual property jointly invented and developed as a result of the projects will be owned jointly by the University and the Company. The Agreement has an initial term of five (5) years, and is renewable upon mutual agreement of the parties.
 
On March 4, 2015, we entered into a Patent License Agreement (PLA) with the University of Texas at El Paso (UTEP) regarding our joint research and development of CTLA-4 Blockade with Metronomic Chemotherapy for the Treatment of Breast Cancer. This is the first PLA with UTEP following our Collaborative Agreement with them dated May 9, 2012, and memorializes the joint ownership of the applicable patent and the financial and other terms related thereto.
 
On June 19, 2015, we entered into Amendment No. 1 to this Agreement, pursuant to which we explicitly included Provisional Patent Application No. 62/161,116 entitled, “Anti-CTLA-4 Blockade” (the “Application”) under the definition of “Patent Rights” as set forth in the PLA. The Application was filed with the United States Patent and Trademarks Office on May 13, 2015; the underlying technology was invented by Robert Kirken and Georgialina Rodriguez, and is solely-owned by The Board of Regents of The University of Texas System.
 
On October 31, 2017 we entered into an Agreement, Final Payment under Contract, and Release of all Claims, whereby we agreed to pay them a total of $326,336 arising out of the research and development agreements with an initial payment of $22,211, and monthly payments of varying amounts between $5,000 and $20,000 thereafter for twenty eight months until the balance is paid in full. Subject to the compliance of all terms, the intellectual property rights established and arising out of the collaborative agreements remain in full force and effect and the parties agreed to a mutual release upon the final contracted payment. The full amount of the liability has been recognized as an accounts payable, with $285,024 outstanding as of the date of this filing.
 
 
14
Premier Biomedical, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
 
Note 10 – Changes in Stockholders’ Equity (Deficit)
 
Reverse Stock Split
On June 27, 2018, the Company effected a 1-for-250 reverse stock split (the “Reverse Stock Split”). No fractional shares were issued, and no cash or other consideration was paid in connection with the Reverse Stock Split. Instead, the Company issued one whole share of the post-Reverse Stock Split common stock to any stockholder who otherwise would have received a fractional share as a result of the Reverse Stock Split. The Company was authorized to issue 1,000,000,000 shares of common stock prior to the Reverse Stock Split, which remains unaffected. The Reverse Stock Split did not have any effect on the stated par value of the common stock, or the Company’s authorized preferred stock. Unless otherwise stated, all share and per share information in this Quarterly Report on Form 10-Q has been retroactively adjusted to reflect the Reverse Stock Split.
 
Convertible Preferred Stock, Series A
The Company has 10,000,000 authorized shares of Preferred Stock, of which 2,000,000 shares of $0.001 par value Series A Convertible Preferred Stock (“Series A Preferred Stock”) have been designated. Each share of Series A Preferred Stock is convertible, at the option of the holder thereof, at any time after the issuance of such share into one (1) fully paid and non-assessable share of Common Stock. Each outstanding share of Series A Preferred Stock is entitled to one hundred (100) votes per share on all matters to which the shareholders of the Corporation are entitled or required to vote. The Company shall reserve and keep available out of its authorized but unissued shares of Common Stock such number of shares sufficient to effect the conversions.
 
Common Stock
The Company has one billion authorized shares of $0.00001 par value Common Stock, as increased pursuant to an amendment to the articles of incorporation on February 9, 2016.
 
Common Stock Issuances for Debt Conversions
On January 29, 2018, the Company issued 106,238 shares of common stock pursuant to the conversion of $40,000 of principal from the Second SEG Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized.
 
On January 3, 2018, the Company issued 76,923 shares of common stock pursuant to the conversion of $25,000 of principal from the First RDW Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized.
 
Common Stock Issuances on Subscriptions Payable
On various dates from January 17, 2018 through February 13, 2018, the Company issued a total of 254,703 shares to The Special Equities Group and DiamondRock, LLC as compensation valued at $273,805 awarded on December 6, 2017.
 
Note 11 – Income Taxes
 
The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences.
 
For the six months ended June 30, 2018, and the year ended December 31, 2017, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At June 30, 2018, and December 31, 2017, the Company had approximately $5,015,000 and $4,860,000 of federal net operating losses, respectively. The net operating loss carry forwards, if not utilized, will begin to expire in 2031.
 
 
15
Premier Biomedical, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
 
The components of the Company’s deferred tax asset are as follows:
 
 
 
June 30,
 
 
December 31,
 
 
 
2018
 
 
2017
 
Deferred tax assets:
 
 
 
 
 
 
Net operating loss carry forwards
 $1,050,000 
 $1,701,000 
 
 
 
    
    
Net deferred tax assets before valuation allowance
 $1,050,000 
 $1,701,000 
Less: Valuation allowance
  (1,050,000)
  (1,701,000)
Net deferred tax assets
 $- 
 $- 
 
Based on the available objective evidence, including the Company’s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at June 30, 2018, and December 31, 2017, respectively.
 
A reconciliation between the amounts of income tax benefit determined by applying the applicable U.S. and state statutory income tax rate to pre-tax loss is as follows:
 
 
 
June 30,
 
 
December 31,
 
 
 
2018
 
 
2017
 
 
 
 
 
 
 
 
Federal and state statutory rate
  21%
  35%
Change in valuation allowance on deferred tax assets
  (21%)
  (35%)
 
In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.
 
Note 12 – Subsequent Events
 
Convertible Debt Financing
On July 11, 2018, we received $120,000 from Red Diamond Partners LLC from the sale of an 8% interest bearing; unsecured convertible promissory note maturing on October 31, 2018 (“Third Red Diamond Note”). The note is convertible at 60% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
 
On July 11, 2018, we received $60,000 from SEG-RedaShex, LLC from the sale of an 8% interest bearing; unsecured convertible promissory note maturing on October 31, 2018 (“Third SEG-RedaShex Note”). The note is convertible at 60% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
 
Common Stock Issuances for Debt Conversions
On August 15, 2018, the Company issued 100,000 shares of common stock pursuant to the conversion of $6,000 of principal from the Third Red Diamond Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized.
 
On August 9, 2018, the Company issued 83,333 shares of common stock pursuant to the conversion of $5,000 of principal from the Third Red Diamond Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized.
 
On July 27, 2018, the Company issued 83,333 shares of common stock pursuant to the conversion of $10,000 of principal from the Third Red Diamond Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized.
 
 
 

 
16
 
ITEM 2 
Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
Our Management’s Discussion and Analysis contains not only statements that are historical facts, but also statements that are forward-looking (within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Forward-looking statements are, by their very nature, uncertain and risky. These risks and uncertainties include international, national and local general economic and market conditions; demographic changes; our ability to sustain, manage, or forecast growth; our ability to successfully make and integrate acquisitions; raw material costs and availability; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to protect technology; and other risks that might be detailed from time to time in our filings with the Securities and Exchange Commission.
 
Although the forward-looking statements in this Quarterly Statement reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by them. Consequently, and because forward-looking statements are inherently subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this report and in our other reports as we attempt to advise interested parties of the risks and factors that may affect our business, financial condition, and results of operations and prospects.
 
The following discussion and analysis of financial condition and results of operations of the Company is based upon, and should be read in conjunction with, its unaudited financial statements and related notes elsewhere in this Form 10-Q, which have been prepared in accordance with accounting principles generally accepted in the United States.
 
Summary Overview
 
We were strictly a research-based company that intended to discover cures for PTSD, cancer and various other diseases. In order to fund on-going research and development in our Biologics Division, we developed a line of hemp oil based topical pain relief products. We began in January of 2017 with a single product and currently have eight topical pain relief products.
 
Through our continued development and expansion of proprietary drugs and treatments, we have reorganized the company into four technology centers: (1) PTSD, (2) Anti-Cancer Drugs, (3) Anti-Aging Treatments, and (4) Topical Pain Relief Products.
 
Pain Management Products
 
We have developed and are now marketing all-natural, hemp-oil based products that are pesticide and solvent free. These products provide generalized, neuropathic and localized topical pain relief.
 
In the past year we have rapidly expanded our product offerings, and we now offer eight pain relief products:
 
1.
96-hour pain relief patch with 50 mg of hemp oil extract, the highest level of pain relief ingredient available in the industry;
 
2.
120 mg/ 10 ml water-based roll-on applicator;
 
3.
150 mg/ 10 ml oil-based roll-on applicator;
 
 
17
 
 
4.
150 mg/ 30 ml oil-based pump spray applicator;
 
5.
150 mg/ 2 oz. ointment;
 
6.
200 mg/10 ml oil-based roll-on applicator;
 
7.
500 mg/ 30 ml oil-based pump spray applicator; and
 
8.
500 mg/ 1 oz. ointment.
 
We believe that this eight-product array positions us favorably in the topical pain relief marketplace. The topical pain relief market is expected to grow rapidly in the next few years, due to the focus on reduction of opioid pain medication use, and we intend to be a major player in that expanding market.
 
Now that we have completed the product design and development phase, we are aggressively embarking on the product distribution and sales phase by:
 
1.
Expanding our online sales beyond our web site at: www.painreliefmeds.com;
 
2.
Securing the services of a social media coordinator to ensure that we optimize that promotional tool;
 
3.
Recruiting a National Sales Director to coordinate our growing field of sales representatives and distributors;
 
4.
Securing the services of a sales organization with expertise in marketing to the government and senior care facilities;
 
5.
Engaging an investor relations firm to facilitate television appearances designed to gain optimum exposure for our company and its products;
 
6.
Appearing in radio and television broadcasts, and podcasts, via Uptick Newswire periodically to ensure that our story gets out to the public; and
 
7.
Retaining the services of marketing firms to promote the Company and its products through social media.
 
In addition, we are in the process of negotiating potential partnerships outside the United States to manufacture and market our products worldwide. We anticipate that these partnerships will make new markets available to us and allow us to rapidly increase our sales and profitability through favorable manufacturing arrangements.
 
Customers indicate that they were able to achieve pain relief from our products and stop the use of opioid painkillers. Public awareness of the harmful side effects of opioid painkillers has grown significantly, and many states have initiated litigation against drug makers claiming they misrepresented the risks of opioid painkillers.1 As patients seek to cut back their use of opioid painkillers and look for alternatives, we believe demand for our products will see a significant increase. We intend to petition national insurance agencies to urge them to consider covering the use of our all-natural pain relief products as a safe alternative to opioid painkillers.
 
(1)
See Oklahoma Sues Opioid Drugmakers; New Hampshire Presses Epidemic Probe, by Heide Brandes and Nate Raymond, Reuters, available at https://www.reuters.com/article/us-oklahoma-drugs-idUSKBN19L2HJ.
 
 
18
 
 
Financing
 
In the past, as we worked through the development of our products, we have relied heavily on financing through various issuances of common stock, warrants and convertible debt. As our sales grow, we expect to find financing solutions in the future that help us expand our operations, avoid dilution to our shareholders, and ultimately increase our company valuation.
 
On March 1, 2018, we received $60,000 from the sale of convertible notes to two investors. On April 24, 2018, the investors bought additional convertible notes for an aggregate of $60,000 when we filed a registration statement to cover the shares of common stock issuable upon conversion of their convertible notes. On July 11, 2018, these investors provided us with an additional $180,000 for convertible notes in the third and final tranche of their commitment to us.
 
Despite the recent sales of convertible notes, our goal is to move forward with more favorable financing as we begin to grow our revenues. To date, the cash generated by these new products is not yet sufficient to finance our volume ramp-up and planned product introductions.
 
Through 2018, we will continue to market our pain management products and seek a wider distribution network through the negotiation of distribution agreements with large pharmacy chains, military branches, government agencies, senior care facilities and international partners.
 
Through our reorganization into four technology centers, we are positioned to take advantage of opportunities to individually sell, license or commercialize the technologies produced within each of these centers to suitable investment partners, without dilutive equity issuances. In the long run, we believe that this will be most beneficial to our investors.
 
Going Concern
 
As a result of our current financial condition, we have received a report from our independent registered public accounting firm for our financial statements for the years ended December 31, 2017 and 2016 that includes an explanatory paragraph describing the uncertainty as to our ability to continue as a going concern. In order to continue as a going concern we must effectively balance many factors and generate more revenue so that we can fund our operations from our sales and revenues. If we are not able to do this we may not be able to continue as an operating company. We recently completed the sale of convertible notes to raise $180,000. This should give us the capital we need in the short term to push forward in the production and marketing of our new pain management products. However, if we are unable to grow revenues sufficient to meet our operating expenses, we must again raise capital by issuing debt or through the sale of our stock. There is no assurance that our cash flow will be adequate to satisfy our operating expenses and capital requirements.
 
Results of Operations for the Three and Six Months Ended June 30, 2018 and 2017
 
Introduction
 
We had revenues from our pain management products of $12,089 and $22,484 for the three and six months ended June 30, 2018, respectively. Our cost of goods sold were $10,146 and $16,204, respectively, for the three and six months ended June 30, 2018, respectively. We had no revenues or cost of goods sold for the three and six months ended June 30, 2017. Our operating expenses were $81,541 and $155,649, respectively, for the three and six months ended June 30, 2018, compared to $85,855 and $160,061, respectively, for the three and six months ended June 30, 2017, a decrease of $4,314 and $4,412, or 5% and 3%, respectively. Our operating expenses were relatively steady during these periods.
 
 
19
 
 
Our results of operations for the three and six months ended June 30, 2018 and 2017 were as follows:
 
 
 
Three Months
 
 
Three Months
 
 
Six Months
 
 
Six Months
 
 
 
June 30,
 
 
June 30,
 
 
June 30,
 
 
June 30,
 
 
 
2018
 
 
2017
 
 
2018
 
 
2017
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue
 $12,089 
 $- 
 $22,484 
 $- 
Cost of goods sold
  10,146 
  - 
  16,204 
  - 
Gross profit
  1,943 
  - 
  6,280 
  - 
 
    
    
    
    
Operating expenses:
    
    
    
    
General and administrative
  42,817 
  40,246 
  77,309 
  73,305 
Professional fees
  38,724 
  45,609 
  78,340 
  86,756 
Total operating expenses
  81,541 
  85,855 
  155,649 
  160,061 
 
    
    
    
    
Net operating loss
  (79,598)
  (85,855)
  (149,369)
  (160,061)
Other income (expense)
  (20,408)
  (1,161,610)
  615,687 
  (6,416,506)
 
    
    
    
    
Net income (loss)
 $(100,006)
 $(1,247,465)
 $466,318 
 $(6,576,567)
 
Revenues
 
The Company was established on May 10, 2010, and began to generate revenues during the third quarter of 2017 from the sale of pain patches made with CBD oils. Our sales are comprised of both website sales to individual consumers and wholesale transactions with brick and mortar pharmacies, while our cost of goods sold primarily consists of the products and the packaging. We had revenues of $12,089 and $22,484 for the three and six months ended June 30, 2018, respectively. While we did have sales through a joint venture in early 2017, we had not yet recognized any revenue directly prior to June 30, 2017.
 
Cost of Goods Sold
 
Cost of goods sold for the three and six months ended June 30, 2018 were $10,146 and $16,204. There were no cost of goods sold for the comparative periods in 2017. Cost of sales consists primarily of product materials and packaging supplies. The increased cost of sales in the periods ended June 30, 2018 was due to the commencement of operations that were not present in the comparative periods in 2017.
 
General and Administrative
 
General and administrative expenses were $42,817 and 77,309, respectively, for the three and six months ended June 30, 2018, compared to $40,246 and $73,305, respectively, for the three and six months ended June 30, 2017, an increase of $2,571 and $4,004, or 6% and 5%, respectively.
 
Professional Fees
 
Professional fees expense was $38,724 and $78,340, respectively, for the three and six months ended June 30, 2018, compared to $45,609 and $86,756, respectively, for the three and six months ended June 30, 2017, a decrease of $6,885 and $8,416, or 15% and 10%, respectively. Professional fees consist primarily of legal and, accounting and auditing services.
 
 
20
 
 
Net Operating Loss
 
Net operating loss was $79,598 and $149,369, respectively, for the three and six months ended June 30, 2018, compared to $85,855 and $160,061, respectively, for the three and months ended June 30, 2017, a decrease of $6,257 and $10,692, or 7% and 7%, respectively. Net operating loss decreased, as set forth above, primarily due to decreased professional fees.
 
Other Income/Expense
 
Other income (expense) was ($20,408) and $615,687, respectively, for the three and six months ended June 30, 2018, compared to ($1,161,610) and ($6,416,506), respectively, for the three and six months ended June 30, 2017, an increase of $1,141,202 and $7,014,487, respectively. Other expense for the three months ended June 30, 2018 consisted of interest expense of $73,554, as offset by a gain of $53,146 in market value of derivative liabilities. The other expense of $1,161,610 for the three months ended June 30, 2017 consisted of interest expense of $600 and a loss of $1,161,010 in market value of the warrants.
 
Other income for the six months ended June 30, 2018 consisted of a gain of $753,386 in market value of derivative liabilities, as offset by interest expense of $137,699. The other expense of $6,416,506 for the six months ended June 30, 2017 consisted of interest expense of $153,347, a loss of $6,261,101 in market value of the warrants and an investment loss of $2,058 in our terminated joint venture.
 
Net Income (Loss)
 
Net income (loss) for the three and six months ended June 30, 2018, was ($100,006) or ($0.03) per share, and $466,318 or $0.16 per share, respectively, compared to ($1,247,465) or ($0.62) per share, and ($6,576,567) or ($3.64) per share, respectively, for the three and six months ended June 30, 2017. Net loss decreased, as set forth above, primarily due to the difference between loss in value of our derivative liabilities of ($1,161,010) and ($6,261,101) for the three and six months ended June 30, 2017, respectively, and the gain in value of our derivative liabilities of $53,146 and $753,386 for the three and six months ended June 30, 2018, respectively.
 
Liquidity and Capital Resources
 
Introduction
 
During the three and six months ended June 30, 2018, we had negative operating cash flows. Our cash on hand as of June 30, 2018 was $10,319, which was derived from the sale of shares of common stock, warrants and convertible promissory notes to investors. Our monthly cash flow burn rate for 2017 was approximately $42,500, and our monthly burn rate through the six months ended June 30, 2018 was approximately $26,000. We have strong short-term cash needs as we ramp up production and sales of our new products. We will face strong medium to long term cash needs as we continue to grow the business. We anticipate that these needs will be satisfied through the issuance of debt or the sale of our securities until such time as our cash flows from operations will satisfy our cash flow needs.
 
 
21
 
 
Our cash, current assets, total assets, current liabilities, and total liabilities as of June 30, 2018 and December 31, 2017, respectively, are as follows:
 
 
 
June 30,
 
 
December 31,
 
 
 
 
 
 
2018
 
 
2017
 
 
Change
 
 
 
 
 
 
 
 
 
 
 
Cash
 $10,319 
 $83,704 
 $(73,385)
Total Current Assets
  169,509 
  203,603 
  (34,094)
Total Assets
  175,822 
  209,081 
  (33,259)
Total Current Liabilities
  2,202,960 
  2,819,807 
  (616,847)
Total Liabilities
 $2,202,960 
 $2,819,807 
 $(616,847)
 
Our cash and total current assets decreased as we continued to sustain losses. Our total current liabilities decreased primarily due to a reduction of $669,382 in the value of our derivative liability. Our working capital deficit decreased from ($2,616,204) to ($2,033,451), and our stockholders’ deficit decreased by $583,588 to ($2,027,138) due primarily to the reduction in the value of our derivative liability as well.
 
In order to repay our obligations in full or in part when due, we will be required to raise significant capital from other sources. There is no assurance, however, that we will be successful in these efforts.
 
Cash Requirements
 
Our cash on hand as of June 30, 2018 was $10,319. Based on our minimal revenues and current monthly burn rate of approximately $26,000 per month, we will need to continue to fund operations by raising capital from the sale of our stock and debt financings.
 
Sources and Uses of Cash
 
Operations
 
We had net cash used in operating activities of $(191,356) for the six months ended June 30, 2018, compared to $(345,667) for the six months ended June 30, 2017. This decrease in net cash used in operating activities was driven primarily by a reduction in prepayments of expenses, as diminished by our increased inventory purchases of $38,653.
 
Investments
 
We had $2,029 net cash used in investing activities for the six months ended June 30, 2018, and $4,752 net cash used in investing activities for the six months ended June 30, 2017. We outsource the manufacturing of our products, so our investment expenses are minimal.
 
Financing
 
Our net cash provided by financing activities for the six months ended June 30, 2018 was $120,000, which consisted of the proceeds from the sale of convertible notes. For the six months ended June 30, 2017, net cash provided by financing was $453,323, which consisted primarily of proceeds from the sale of stock of $435,000 and proceeds of $18,323 from sales of stock pursuant to our equity line of credit with Redwood Management, LLC.
 
 
22
 
 
Securities Purchase Agreement
 
On March 30, 2017, we entered into a Securities Purchase Agreement with three investors and raised $300,000 through the sale of stock and warrants. These same investors purchased $150,000 of common stock and warrants in the second tranche on May 30, 2017. On August 8, 2017, we exchanged convertible notes with the investors for the warrants issued in the first tranche and the common stock issued in the second tranche. We also amended the Securities Purchase Agreement on that date, and on October 30, 2017, the investors purchased an additional $150,000 of our convertible notes. We expect these investments, our growing revenues and sales of common stock, warrants and convertible notes will finance our operations for the next several months as we seek to expand revenues from our new pain management products.
 
Sale of Convertible Notes
 
Pursuant to a separate Securities Purchase Agreement, we sold convertible notes to two investors for $60,000 on each of March 1, 2018 and April 24, 2018 and $180,000 on July 11, 2018, for an aggregate of $300,000.
 
ITEM 3 
Quantitative and Qualitative Disclosures About Market Risk
 
As a smaller reporting company, we are not required to provide the information required by this Item.
 
ITEM 4 
Controls and Procedures
 
(a)            
Disclosure Controls and Procedures
 
We conducted an evaluation, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of June 30, 2018, to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities Exchange Commission’s rules and forms, including to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of June 30, 2018, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses identified and described in our Annual Report on Internal Control Over Financial Reporting filed in our Annual Report on Form 10-K.
 
Our principal executive officers do not expect that our disclosure controls or internal controls will prevent all errors and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives and our principal executive officers are determined to make our disclosure controls and procedures effective at doing so, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented if there exists in an individual a desire to do so. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
 
(b)            
Changes in Internal Control over Financial Reporting
 
No change in our system of internal control over financial reporting occurred during the period covered by this report, the three month period ended June 30, 2018, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
 
 
23
 
 
PART II – OTHER INFORMATION
 
ITEM 1    Legal Proceedings
 
We are not a party to or otherwise involved in any legal proceedings.
 
In the ordinary course of business, we are from time to time involved in various pending or threatened legal actions. The litigation process is inherently uncertain and it is possible that the resolution of such matters might have a material adverse effect upon our financial condition and/or results of operations. However, in the opinion of our management, other than as set forth herein, matters currently pending or threatened against us are not expected to have a material adverse effect on our financial position or results of operations.
 
ITEM 1A     Risk Factors
 
As a smaller reporting company, we are not required to provide the information required by this Item.
 
ITEM 2    Unregistered Sales of Equity Securities and Use of Proceeds
 
Except as previously reported on a Current Report on Form 8-K, we had no unregistered sales of equity securities during the three month period ended June 30, 2018.
 
ITEM 3    Defaults Upon Senior Securities
 
There have been no events which are required to be reported under this Item.
 
ITEM 4    Mine Safety Disclosures
 
Not applicable.
 
ITEM 5    Other Information
 
None.
 
ITEM 6    Exhibits
 
(a)            
Exhibits
 
Exhibit No.
 
Description of Exhibits
 
Certificate of Amendment to the Articles of Incorporation of Premier Biomedical, Inc., dated June 21, 2018
 
 
 
 
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
 
 
 
 
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
 
 
 
 
Chief Executive Officer Certification Pursuant to 18 USC, Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
 
 
Chief Financial Officer Certification Pursuant to 18 USC, Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
 
101.INS
 
XBRL Instance Document
 
 
 
101.SCH
 
XBRL Schema Document
 
 
 
101.CAL
 
XBRL Calculation Linkbase Document
 
 
 
101.DEF
 
XBRL Definition Linkbase Document
 
 
 
101.LAB
 
XBRL Labels Linkbase Document
 
 
 
101.PRE
 
XBRL Presentation Linkbase Document
 
 
24
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
Premier Biomedical, Inc.
 
 
 
 
 
Dated: August 20, 2018
By:  
/s/  William A. Hartman
 
 
 
William A. Hartman
 
 
 
Chief Executive Officer
 
 
 
 
 
 
 
25
EX-3.1 2 biei_ex31.htm CERTIFICATE OF AMENDMENT Untitled Document
 
 Exhibit 3.1
 
 
 
 
EX-31.1 3 biei_ex311.htm CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002 Blueprint
 
EXHIBIT 31.1
 
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
 
I, William A. Hartman, certify that:
 
1.
I have reviewed this Quarterly Report on Form 10-Q of Premier Biomedical, Inc.;
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exhibit Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) 
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) 
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) 
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
 
 
 
 
 
Date: August 20, 2018
By:  
/s/  William A. Hartman
 
 
 
William A. Hartman
 
 
 
Chief Executive Officer
 
 
 
 
EX-31.2 4 biei_ex312.htm CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002 Blueprint
 
EXHIBIT 31.2
 
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
 
I, Heidi H. Carl, certify that:
 
1.
I have reviewed this Quarterly Report on Form 10-Q of Premier Biomedical, Inc.;
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exhibit Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) 
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) 
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) 
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
 
 
 
 
 
Date:  August 20, 2018
By:  
/s/  Heidi H. Carl
 
 
 
Heidi H. Carl
 
 
 
Chief Financial Officer
 
 
 
EX-32.1 5 biei_ex321.htm CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Blueprint
 
EXHIBIT 32.1
 
CERTIFICATION PURSUANT TO 18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
 
 
In connection with the Quarterly Report of Premier Biomedical, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2018, as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, William A. Hartman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:
 
(1)           
The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2)           
Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
 
Date: August 20, 2018
By:  
/s/  William A. Hartman
 
 
 
William A. Hartman
 
 
 
Chief Executive Officer
 

A signed original of this written statement required by Section 906 has been provided to Premier Biomedical, Inc., and will be retained by Premier Biomedical, Inc., and furnished to the Securities and Exchange Commission or its staff upon request.
 
 
EX-32.2 6 biei_ex322.htm CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Blueprint
 
EXHIBIT 32.2
 
CERTIFICATION PURSUANT TO 18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
 OF THE SARBANES-OXLEY ACT OF 2002
 
 
In connection with the Quarterly Report of Premier Biomedical, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2018, as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Heidi H. Carl, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:
 
(1)           
The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2)           
Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
Date:  August 20, 2018
By:  
/s/  Heidi H. Carl
 
 
 
Heidi H. Carl
 
 
 
Chief Financial Officer
 

A signed original of this written statement required by Section 906 has been provided to Premier Biomedical, Inc., and will be retained by Premier Biomedical, Inc., and furnished to the Securities and Exchange Commission or its staff upon request.
 
 
GRAPHIC 7 biei_ex31000.jpg IMAGE begin 644 biei_ex31000.jpg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end EX-101.INS 9 biei-20180630.xml XBRL INSTANCE DOCUMENT 0001515740 2018-01-01 2018-06-30 0001515740 2017-12-31 0001515740 2018-06-30 0001515740 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001515740 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001515740 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001515740 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0001515740 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0001515740 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0001515740 2017-01-01 2017-06-30 0001515740 us-gaap:BoardOfDirectorsChairmanMember 2017-12-31 0001515740 us-gaap:BoardOfDirectorsChairmanMember 2018-06-30 0001515740 2016-12-31 0001515740 2017-01-01 2017-12-31 0001515740 us-gaap:ChiefExecutiveOfficerMember 2017-01-01 2017-12-31 0001515740 us-gaap:BoardOfDirectorsChairmanMember 2017-01-01 2017-12-31 0001515740 us-gaap:BoardOfDirectorsChairmanMember 2018-01-01 2018-06-30 0001515740 us-gaap:ChiefExecutiveOfficerMember 2018-01-01 2018-06-30 0001515740 2018-04-01 2018-06-30 0001515740 2017-04-01 2017-06-30 0001515740 2017-06-30 0001515740 BIEI:ConvertibleNotePayable1Member 2018-06-30 0001515740 BIEI:ConvertibleNotePayable1Member 2017-12-31 0001515740 BIEI:ConvertibleNotePayable2Member 2018-06-30 0001515740 BIEI:ConvertibleNotePayable2Member 2017-12-31 0001515740 BIEI:ConvertibleNotePayable3Member 2018-06-30 0001515740 BIEI:ConvertibleNotePayable3Member 2017-12-31 0001515740 BIEI:ConvertibleNotePayable4Member 2018-06-30 0001515740 BIEI:ConvertibleNotePayable4Member 2017-12-31 0001515740 BIEI:ConvertibleNotePayable5Member 2018-06-30 0001515740 BIEI:ConvertibleNotePayable5Member 2017-12-31 0001515740 BIEI:ConvertibleNotePayable6Member 2018-06-30 0001515740 BIEI:ConvertibleNotePayable6Member 2017-12-31 0001515740 BIEI:ConvertibleNotePayable7Member 2018-06-30 0001515740 BIEI:ConvertibleNotePayable7Member 2017-12-31 0001515740 BIEI:ConvertibleNotePayable8Member 2018-06-30 0001515740 BIEI:ConvertibleNotePayable8Member 2017-12-31 0001515740 BIEI:ConvertibleNotePayable9Member 2018-06-30 0001515740 BIEI:ConvertibleNotePayable9Member 2017-12-31 0001515740 2018-08-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure PREMIER BIOMEDICAL INC 0001515740 10-Q 2018-06-30 false --12-31 No No Yes Smaller Reporting Company Q2 2018 34824 35774 84763 123416 312 0 83704 10319 83704 0 0 10319 0 0 125341 203603 169509 209081 175822 5478 6313 5840 13895 41382 36746 346814 347560 169990 218360 0 169990 0 0 218360 0 2819807 2202960 2255781 1586399 2819807 2202960 2000 2000 26 30 13442255 13833326 -2610726 -2027138 -16328812 -15862494 273805 0 209081 175822 30010 36640 0.001 0.001 0.00001 0.00001 1000000000 1000000000 2551363 2989307 2551363 2989307 254703 0 2000000 2000000 2000000 2000000 10000000 10000000 6280 0 1943 0 22484 0 12089 0 155649 160061 81541 85855 78340 86756 38724 45609 77309 73305 42817 40246 -149369 -160061 -79598 -85855 137699 153347 73554 600 -753386 6261101 -53146 1161010 615687 -6416506 -20408 -1161610 0.16 -3.64 -0.03 -0.62 0.16 -3.64 -0.03 -0.62 2944497 1808032 2989307 2008700 2932577 1808032 2989307 2008700 1194 1191 129644 149456 -950 -130091 -38653 0 312 0 0 1200 8055 2691 -4636 947 746 -57653 -191356 -345667 -2029 -4752 0 18323 0 435000 120000 0 120000 453323 83704 22437 -73385 102904 0 0 0 0 65000 323197 52270 229043 120000 0 <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><u>Basis of Presentation</u></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited, condensed financial statements of Premier Biomedical, Inc. (&#8220;the Company&#8221;) have been prepared pursuant to rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, these statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. It is suggested that these statements be read in conjunction with the financial statements included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31,&#160;2017.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Use of Estimates</u></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Cash and Cash Equivalents</u></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Patent Rights and Applications</u></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patent rights and applications costs include the acquisition costs and costs incurred for the filing of patents. Patent rights and applications are amortized on a straight-line basis over the legal life of the patent rights beginning at the time the patents are approved. Patent costs for unsuccessful patent applications are expensed when the application is terminated.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Fair Value of Financial Instruments</u></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company&#8217;s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Basic and Diluted Loss Per Share</u></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic earnings per share (&#8220;EPS&#8221;) are computed by dividing net income (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Diluted EPS is computed by dividing net income by the weighted average number of common shares and potential common shares outstanding (if dilutive) during each period. Potential common shares include stock options, warrants and restricted stock. The number of potential common shares outstanding relating to stock options, warrants and restricted stock is computed using the treasury stock method.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The reconciliation of the denominators used to calculate basic EPS and diluted EPS for the six months ended June&#160;30,&#160;2018 and 2017 are as follows:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="text-align: center"><font style="font-size: 8pt"><b>For the Six Months Ended</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>June 30,</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 75%; text-align: justify"><font style="font-size: 8pt">Weighted average common shares outstanding &#8211; basic</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">2,932,577</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">1,808,032</font></td> <td style="width: 2%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><font style="font-size: 8pt">Plus: Potentially dilutive common shares:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; text-indent: 0.25in"><font style="font-size: 8pt">Warrants</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">11,920</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><font style="font-size: 8pt">Weighted average common shares outstanding &#8211; diluted</font></td> <td style="padding-bottom: 3pt">&#160;</td> <td style="border-bottom: black 1pt double">&#160;</td> <td style="border-bottom: black 1pt double; text-align: right"><font style="font-size: 8pt">2,944,497</font></td> <td style="padding-bottom: 3pt">&#160;</td> <td style="padding-bottom: 3pt">&#160;</td> <td style="border-bottom: black 1pt double">&#160;</td> <td style="border-bottom: black 1pt double; text-align: right"><font style="font-size: 8pt">1,808,032</font></td> <td style="padding-bottom: 3pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the six months ended June&#160;30, 2017, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share. Warrants excluded from the calculation of diluted EPS because their effect was anti-dilutive were 245,760 and 685,184 as of June&#160;30,&#160;2018 and 2017, respectively.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Stock-Based Compensation</u></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company had no stock based compensation issuances during the six months ended June&#160;30, 2018 and&#160;2017.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Revenue Recognition</u></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales commenced on July 5, 2017 with the termination of our joint venture and are recognized upon shipment of goods, which are typically paid for at the time of order.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Advertising and Promotion</u></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All costs associated with advertising and promoting products are expensed as incurred. These expenses were $20,742 and $25,413 for the six months ended June&#160;30, 2018 and 2017, respectively.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Income Taxes</u></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Uncertain Tax Positions</u></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Various taxing authorities periodically audit the Company&#8217;s income tax returns. These audits include questions regarding the Company&#8217;s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The assessment of the Company&#8217;s tax position relies on the judgment of management to estimate the exposures associated with the Company&#8217;s various filing positions.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Recent Accounting Pronouncements</u></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-07, <i>Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</i>, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The new guidance is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, with early adoption permitted. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2018, the FASB issued ASU No. 2018-05, <i>Income Taxes (Topic 740) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118</i>. The amendment provides guidance on accounting for the impact of the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;) and allows entities to complete the accounting under ASC 740 within a one-year measurement period from the Tax Act enactment date. This standard is effective upon issuance. The Tax Act has several significant changes that impact all taxpayers, including a transition tax, which is a one-time tax charge on accumulated, undistributed foreign earnings. The calculation of accumulated foreign earnings requires an analysis of each foreign entity&#8217;s financial results going back to 1986. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2018, the FASB issued ASU No. 2018-02, <i>Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</i>. The guidance permits entities to reclassify tax effects stranded in Accumulated Other Comprehensive Income as a result of tax reform to retained earnings. This new guidance is effective for annual and interim periods in fiscal years beginning after December 15, 2018. Early adoption is permitted in annual and interim periods and can be applied retrospectively or in the period of adoption. The Company is currently in the process of evaluating the impact of adoption on its consolidated financial statements.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective January 1, 2018, the Company adopted ASC 606 &#8212; Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 &#8212; Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. There was no impact on the Company&#8217;s financial statements as a result of adopting Topic 606 for the six months ended June&#160;30, 2018 and 2017, or the twelve months ended December 31, 2017.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2017, the FASB issued ASU <font style="color: #333333">2017-09<i>,</i></font><i> Compensation &#8212; Stock Compensation (Topic 718): Scope of Modification Accounting.</i> ASU 2017-09, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. <font style="color: #333333">Per ASU 2017-9, a</font>n entity should account for the effects of a modification unless all the following are met: (1) the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification, (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and (3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The current disclosure requirements in Topic 718 apply regardless of whether an entity is required to apply modification accounting under the amendments in ASU 2017-9. <font style="color: #333333">ASU 2017-9 is effective for public business entities for annual and interim periods in fiscal years beginning after December 15, 2017.</font> Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this ASU should be applied prospectively to an award modified on or after the adoption date. The adoption of <i>ASU 2017-9</i> is not expected to have a material impact on the Company&#8217;s financial statements or related disclosures.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No other new accounting pronouncements, issued or effective during the six months ended June&#160;30, 2018, have had or are expected to have a significant impact on the Company&#8217;s financial statements.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As shown in the accompanying financial statements, the Company has no revenues, incurred net losses from operations resulting in an accumulated deficit of $15,862,494, and had negative working capital of ($2,033,451) at June&#160;30, 2018. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company is currently seeking additional sources of capital to fund short term operations. The Company, however, is dependent upon its ability to secure equity and/or debt financing and there are no assurances that the Company will be successful; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company&#8217;s ability to continue as a going concern. The financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Accounts Payable</u></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company owed $34,116 and $40,195 as of June&#160;30,&#160;2018 and December 31, 2017, respectively, to entities owned by the Chairman of the Board of Directors. The amounts are related to patent costs and reimbursable expenses paid by the Chairman on behalf of the Company.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company owed $1,555 as of June&#160;30,&#160;2018 and December 31, 2017, to the Company&#8217;s CEO for reimbursable expenses.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company owed $1,075 and $478 as of June&#160;30,&#160;2018 and December 31, 2017, respectively, amongst members of the Company&#8217;s Board of Directors for reimbursable expenses.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 14, 2017, we formed Premier Biomedical Pain Relief Meds, LLC as a wholly-owned Nevada limited liability company. On January 1, 2018, we contributed our pain management assets to this entity and continued our pain management operations within this new subsidiary.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company amortizes its patent rights and applications on a straight line basis over the expected useful technological or economic life of the patents, which is typically 17 years from the legal approval of the patent applications when there is probable future economic benefits associated with the patent. The Company has elected to expense all of their patent rights and application costs due to difficulties associated with having to prove the value of their future economic benefits. All patent applications are currently pending and the Company has no patents that have yet been approved. It is the Company&#8217;s policy that it performs reviews of the carrying value of its patent rights and applications on an annual basis.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 4, 2015, we entered into a Patent License Agreement (&#8220;PLA&#8221;) with the University of Texas at El Paso (&#8220;UTEP&#8221;) regarding our joint research and development of CTLA-4 Blockade with Metronomic Chemotherapy for the Treatment of Breast Cancer. This is the first PLA with UTEP following our Collaborative Agreement with them dated May&#160;9,&#160;2012, and memorializes the joint ownership of the applicable patent and the financial and other terms related thereto.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 19, 2015, we entered into Amendment No. 1 to this Agreement, pursuant to which we explicitly included Provisional Patent Application No. 62/161,116 entitled, &#8220;Anti-CTLA-4 Blockade&#8221; (the &#8220;Application&#8221;) under the definition of &#8220;Patent Rights&#8221; as set forth in the PLA. The Application was filed with the United States Patent and Trademarks Office on May 13, 2015; the underlying technology was invented by Robert Kirken and Georgialina Rodriguez, and is solely-owned by The Board of Regents of The University of Texas System.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The Company has certain financial instruments that must be measured under the new fair value standard. The Company&#8217;s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows:</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June&#160;30, 2018 and December 31, 2017, respectively:&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="8" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Fair Value Measurements at June&#160;30, 2018</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Level 1</font></td> <td style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Level 2</font></td> <td style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Level 3</font></td></tr> <tr style="vertical-align: bottom"> <td style="width: 48%; padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 31.5pt"><font style="font: 8pt Times New Roman, Times, Serif"><b>Assets</b></font></td> <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Cash</font></td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10,319</font></td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 10.25pt"><font style="font: 8pt Times New Roman, Times, Serif">Total assets</font></td> <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10,319</font></td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&
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biei_ex31001.jpg IMAGE begin 644 biei_ex31001.jpg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